## ZTS: Zoetis Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.5% below STRENGTH zone (3.0-6.0%); PEG 2.37 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($120.58)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Voya Investment Management LLC Sells 2,335,093 Shares of Elanco Animal Health Incorporated $ELAN**
- Source: MarketBeat | 20251231T130831 | Somewhat-Bullish | Relevance: 61%
- Voya Investment Management LLC significantly reduced its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by selling 2,335,093 shares, retaining 60,007 shares. Despite this, company insiders have shown recent buying interest, acquiring 43,450 shares in the last three months. Elanco also surpassed its Q3 earnings estimates and received a "Moderate Buy" consensus rating from analysts with a target price of $23.78.

**2. RadNet, Inc. (NASDAQ:RDNT) Receives Average Rating of "Moderate Buy" from Analysts**
- Source: MarketBeat | 20260101T090927 | Somewhat-Bullish | Relevance: 59%
- RadNet, Inc. (NASDAQ:RDNT) has received an average "Moderate Buy" rating from nine analysts, with a consensus one-year price target of $87.60. Despite insiders selling 50,000 shares in the last three months, institutional investors own 77.90% of the company's stock, and insiders retain about 5.6%. RadNet recently missed EPS consensus but beat revenue expectations, reporting $522.9M, a 13.4% year-over-year increase.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $136 | $0 | 0% |
| 2025-12-03 | BTIG | $160 | $160 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Equal-Weight |
| 2025-12-03 | BTIG | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 8 ($0.32M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+1.0%)
- Blackrock Inc.: 8.2% (-2.8%)
- State Street Corpora: 4.5% (-0.5%)
- Morgan Stanley: 3.8% (-4.3%)
- State Farm Mutual Au: 3.6% (0.0%)

### Key Risks

1. Long-term trend broken: trading 14.5% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 2.37 elevated, pricing in significant growth expectations. Forward P/E 18.6x stretched relative to 7% growth. Quality metrics strong (ROE 50%, ROA 15%, margin 28%). Balance sheet: strong liquidity (3.6x). Institutional flow bearish (7 selling vs 2 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $55.8B |
| Beta | 0.97 |
| 52W Range | $115.25 - $177.40 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.37 |
| Forward P/E | 18.6 |
| Current P/E | 19.9 |
| YoY Growth | 6.9% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at 1.5% (minimal 5-day change). Below STRENGTH zone by 1.5pp (needs >3.0% for momentum thesis). MRS_5 at 0.6% confirms short-term momentum alignment. Below SMA200 (0.85x), long-term trend not supportive. MACD histogram positive (0.89), confirming momentum. RSI neutral at 56. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.54% (CS: 68) | Neutral |
| RSI_14 | 55.5 | Neutral |
| MACD Histogram | 0.89 | Bullish |
| vs SMA20 | 1.031x | Above |
| vs SMA50 | 0.998x | Below |
| vs SMA200 | 0.855x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $125.92
- **Stop Loss:** $120.58 (4.2% risk)
- **Target:** $131.26 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 269
- **Position Value:** $33,872.48
- **Portfolio %:** 33.87%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.62 | $1.70 | +4.8% |
| 2025Q2 | $1.61 | $1.76 | +9.2% |
| 2025Q1 | $1.40 | $1.48 | +5.8% |
| 2024Q4 | $1.36 | $1.40 | +2.8% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_10*